Piper Sandler raised the price target for the Replimune Group Inc (NASDAQ:REPL) stock to “an Overweight”. The rating was released on April 17, 2023, according to finviz. The research report from BTIG Research has resumed the stock to Buy, with a price target set at $60. The stock was initiated by BTIG Research, who disclosed in a research note on November 17, 2020, to Buy and set the price objective to $60. In their research brief published November 02, 2020, Jefferies analysts initiated the Replimune Group Inc stock to Buy with a price target of $67.
The latest trade, Performances and Moving Averages give us the following Picture
The firm’s stock price fluctuated 27.74% within the last five trades and 15.11% within the last 30 trades, which was a significant change from the beginning of this year. Despite the fact that the share price increased 14.86% in the last 6 months and 44.09% was added to its value over the previous 3 months. REPL stock is trading at a margin of 20.46%, 42.59% and 13.73% apart from the 20-Day, 50-Day and 200-Day Simple Moving Average prices.
As of the close of trading, REPL deals in the Healthcare domain. The stock is trading -53.35 percent below its 52-week high and 110.57 percent above its 52-week low. For example, looking both at the price and the high and low measurements of 52 weeks will give you a clearer picture of the direction the price is heading. The firm’s Weighted Alpha is -43.32. A positive weighted alpha indicates the firm has done well over the course of the year, whereas one below 0 indicates that the firm has done poorly.
What Does Replimune Group Inc’s Profitability and Valuation Ratios Tell Us About the Stock?
With regard to the profitability of the company, the operating margin is currently at 0.00 percent. The profit margin, also known as the revenue ratio or gross profit ratio, is an efficiency figure used to estimate the business’s profitability by comparing net income and sales. The higher the number, the more profits are generated for the company and vice versa.
The stock’s market cap achieved a total value of $636.31 million as of the last trading session. Market capitalization is the total value of all outstanding shares of a corporation and it is used to measure a company’s market value. The firm managed a Price-to-Book ratio of 1.70, which equates the market value of a stock with its book value.
Is Insider Trading a Real Thing?
Almost all investors and traders prefer to invest in shares controlled by the management of a corporation as a management company will be more likely to run the business itself and to never conduct things against the management’s desires and will always try to do what is best for their shareholders. Currently, 26.13 percent of Replimune Group Inc shares are owned by insiders, and 82.18 percent are held by financial institutions. Xynos Konstantinos, the Chief Medical Officer at Replimune Group Inc (REPL) has sold 15,881 shares of firm on Jun 07 ’24 at a price of $7.50 against the total amount of $0.12 million. In another inside trade, Astley-Sparke Philip, Executive Chairman of Replimune Group Inc (NASDAQ:REPL) sold 37,928 shares of the firm on May 16 ’24 for a total worth of $0.25 million at a price of $6.47. An inside trade which took place on May 16 ’24, Chief Executive Officer of Replimune Group Inc Patel Sushil sold 20,194 shares of firm against total price of $0.13 million at the cost of $6.47 per share.